contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment CompanyTagList on Company {
  pageUrl
  name
  viewerIsFollowing
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    ...CompanyTagList
    id
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls {
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      defaultInstrument {
        isin
        id
      }
      id
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    id
    name
    viewerIsFollowing
    defaultInstrument {
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


reclassification-of-class-c-shares-to-ordinary-shares-and-transfer-of-ordinary-shares-within-the-framework-of-a-long-term-incentive-plan-2

__typename

title

isPremium

lang

htmlBody

companies

createdAt

publishers

authors

reactionGroups

pageUrl

alternatePageUrls

imgUrl

description

Biotage is active in biotechnology. The company provides solutions in chromatography, organic synthesis, and sample preparation. The company has operations on a global level, mainly concentrated in Europe, North America, and Asia, and a large part of the projects are also conducted in collaboration with other players in the said market. Customers are found in health and care, as well as in the food industry.

Biotage

Uppsala, Sweden – July 17, 2024 – The Annual General Meeting of Biotage AB (publ) (“Biotage”) resolved on April 28, 2021 to adopt a long-term incentive plan (“LTIP 2021”) which has now expired...

<div class="mfn-preamble"><p><strong>Uppsala, Sweden – July 17, 2024 – The Annual General Meeting of Biotage AB (publ) (“Biotage”) resolved on April 28, 2021 to adopt a long-term incentive plan (“LTIP 2021”) which has now expired and for this reason, a total of 31,628 ordinary shares are transferred free of charge to the participants in LTIP 2021. To cover tax costs associated with LTIP 2021, some participants intend to sell a number of shares through Danske Bank A/S on Nasdaq Stockholm and, correspondingly, the company transfers a maximum of 9,459 ordinary shares to cover social contribution costs associated with LTIP 2021 which is expected to take place during the period July 18, 2024 until July 24, 2024, at a price within the registered price range at the relevant time. In order to enable the transfer of own ordinary shares, the Board of Directors has resolved to reclassify 41,087 class C shares into 41,087 ordinary shares in accordance with the reclassification provision in the company’s Articles of Association.</strong></p></div><div class="mfn-body"><p>The company’s holding of own class C shares previously amounted to 659,510. Following the conversion of 41,087 class C shares and transfer of the corresponding number of ordinary shares, Biotage will hold 618,423 own class C shares.</p></div><div class="mfn-footer mfn-e7343beb9afa"><p><strong class="mfn-heading-1">Contacts</strong></p><hr><p>Torben Jörgensen, Interim President &amp; CEO <br>Tel: +46-707 49 05 84, <a rel="noopener" href="mailto:torben.jorgensen@biotage.com">torben.jorgensen@biotage.com</a></p></div><div class="mfn-footer mfn-about mfn-0a7046178eae"><p><strong class="mfn-heading-1">About Biotage</strong></p><hr><p>Biotage is the Global Go-To Separations Company, supporting customers from drug discovery and development through to diagnostics and analytical testing with intelligent and sustainable workflow solutions. Our expertise and top-tier separation solutions play a key role in streamlining our customers’ workflows and improving their outcomes. </p><p>Headquartered in Sweden, Biotage operates globally with 700 employees, serving over 80 countries. Our company is listed on NASDAQ Stockholm (BIOT).<br>Website: <a rel="noopener" href="https://www.biotage.com">www.biotage.com</a></p></div><div class="mfn-footer mfn-regulatory mfn-regulatory-lhfi"><p><em>This information is information that Biotage is obliged to make public pursuant to the Financial Instruments Trading Act. The information was submitted for publication at 2024-07-31 17:30 CEST.</em></p></div><div class="mfn-footer mfn-attachment mfn-attachment-general"><p><strong class="mfn-heading-1">Attachments</strong></p><hr><p><a rel="noopener" href="https://storage.mfn.se/1ce867ff-2e28-4822-a4b0-a1df87bacd5a/reclassification-of-class-c-shares-to-ordinary-shares-and-transfer-of-ordinary-shares-within-the-framework-of-a-long-term-incentive-plan.pdf" class="mfn-generated mfn-primary">Reclassification of class C shares to ordinary shares and transfer of ordinary shares within the framework of a long-term incentive plan</a></p></div>

Reclassification of class C shares to ordinary shares and transfer of ordinary shares within the framework of a long-term incentive plan

Wall Streetin arvostustasoihin verrattuna Eurooppakin näyttää nyt houkuttelevalta

Federal Reserven korkopäätös: Kiire loppui tähän

Lääkekehityssijoittaminen: Arvonluonti yrityskaupoilla ja lisensointisopimuksilla

EKP:n korkopäätös: Keskuspankki ilman rajoitteita

Euroalueen ostopäälliköt: Onks sen jälkeen vielä mäki?

Pysy ajantasalla Inderesin uutiskirjeillä